Kalaris Therapeutics, Inc. (KLRS) Stock Forecast
KLRS analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 8 analysts
- Price target
- $18.71 average of analyst targets
- Upside to target
- +835.7% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.51
- 52-week range
- $2.00 – $10.98
KLRS analyst ratings
8 analystsNumber of analysts at each rating.
KLRS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
KLRS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.52 | −$0.57 | −$0.40 | −$0.64 | +19.3% | 8 |
| Current fiscal year (2026) | −$2.00 | −$2.08 | −$1.85 | −$2.85 | +29.8% | 8 |
| Next fiscal year (2027) | −$1.65 | −$2.20 | $0.70 | −$2.00 | +17.4% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
KLRS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 7 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 7 |
| Next fiscal year (2027) | $11.4M | $0 | $80.0M | 0.0% | 7 |
KLRS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
KLRS revenue: reported and forecast
KLRS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.52 | −$0.52 | −$0.52 | −$0.52 | −$0.52 | −0.2% | 4 up · 2 down |
| Current fiscal year (2026) | −$2.03 | −$2.03 | −$2.01 | −$2.01 | −$2.00 | −1.2% | 5 up · 1 down |
| Next fiscal year (2027) | −$1.63 | −$1.63 | −$1.66 | −$1.66 | −$1.65 | +1.6% | 2 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
KLRS earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; KLRS beat in 7 of 12.
What analysts expect from KLRS
8 analysts cover Kalaris Therapeutics; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $18.71, 835.7% above the latest close of $2.00. Analysts expect earnings of −$2.00 per share for 2026, +29.8% from a year earlier. For 2027 the average estimate is −$1.65 per share on revenue of $11.4 million. Kalaris Therapeutics beat the EPS estimate in 7 of the last 12 quarters.
Related: KLRS income statement, KLRS key metrics, KLRS chart. See the KLRS stock overview for the latest quote and news.
KLRS forecast FAQ
What is Kalaris Therapeutics's price target?
The average analyst price target for Kalaris Therapeutics is $18.71, 835.7% above the latest close of $2.00.
Is Kalaris Therapeutics a buy, hold or sell?
Of 8 analysts covering Kalaris Therapeutics, 5 rate it a strong buy, 2 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Kalaris Therapeutics's EPS forecast?
Analysts forecast −$2.00 per share for 2026 (range −$2.08 to −$1.85); for 2027 the estimate is −$1.65.
When does Kalaris Therapeutics report earnings?
Kalaris Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-0.51.
Does Kalaris Therapeutics usually beat earnings estimates?
Kalaris Therapeutics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.